Switzerland
Switzerland
Explore linked clinical trials.288 results · Page 1 of 12
Cities
Swipe the table sideways for more columns.
| Cities | City | Country | Linked trials |
|---|---|---|---|
| Aarau | Aarau | Switzerland | 1 |
| Aarau | Aarau | Switzerland | 96 |
| Aarau | Aarau | Switzerland | 2 |
| Aarau | Aarau | Switzerland | 1 |
| Aarau | Aarau | Switzerland | 1 |
| Aarau | Aarau | Switzerland | 34 |
| Aarau | Aarau | Switzerland | 1 |
| Aarberg | Aarberg | Switzerland | 1 |
| Allschwil | Allschwil | Switzerland | 1 |
| Allschwil | Allschwil | Switzerland | 1 |
| Altdorf | Altdorf | Switzerland | 1 |
| Arlesheim | Arlesheim | Switzerland | 1 |
| Arzo | Arzo | Switzerland | 2 |
| Bad Zurzach | Bad Zurzach | Switzerland | 1 |
| Bad Zurzach | Bad Zurzach | Switzerland | 1 |
| Baden | Baden | Switzerland | 1 |
| Baden | Baden | Switzerland | 68 |
| Baden | Baden | Switzerland | 18 |
| Barmelweid | Barmelweid | Switzerland | 1 |
| Barmelweid | Barmelweid | Switzerland | 1 |
| Barmelweid | Barmelweid | Switzerland | 1 |
| Basel | Basel | Switzerland | 499 |
| Basel | Basel | Switzerland | 26 |
| Basel | Basel | Switzerland | 4 |
| Basel | Basel | Switzerland | 2 |
2,249 results · Page 1 of 90
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Clinical Trial of MK-2010 With Sacituzumab Tirumotecan (Sac-TMT) in Participants With Solid Tumors (MK-2010) | cancer, neoplasm | Recruiting | Phase 2 | 2026-10-09 | NCT07785609 | |
| Acute Effects of Intravenous 5-MeO-DMT in Healthy Participants | 5-methoxy-dimethyltryptamine (5-MeO-DMT) | Recruiting | Phase 1 | 2026-10-09 | NCT07444788 | |
| A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, bone marrow disorder, hematologic disorder, primary myelofibrosis | Recruiting | Phase 3 | 2026-10-09 | NCT07357727 | |
| A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colonic neoplasm, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Recruiting | Phase 3 | 2026-10-09 | NCT07284849 | |
| Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder | Recruiting | Phase 3 | 2026-10-09 | NCT07214779 | |
| Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 2 / Phase 3 | 2026-10-09 | NCT07100080 | |
| EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS) | PIK3CA-related Overgrowth Spectrum (PROS) | Recruiting | Phase 2 | 2026-10-09 | NCT06997588 | |
| European Real-World Registry for Use of the Ion Endoluminal System | Neoplasms by Site, Thoracic Neoplasms, lung cancer, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm | Recruiting | Not stated | 2026-10-09 | NCT06923774 | |
| Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | Bacterial Infections and Mycoses, Infections, Skin and Connective Tissue Diseases, Suppuration, bacterial infectious disease, hidradenitis, hidradenitis suppurativa, skin disease caused by bacterial infection, skin disorder, skin disorder caused by infection, sweat gland disorder | Recruiting | Phase 3 | 2026-10-09 | NCT06855498 | |
| A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD) | Crohn disease, Digestive System Diseases, colitis, colonic disorder, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder, ulcerative colitis | Recruiting | Phase 3 | 2026-10-09 | NCT06405087 | |
| Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Metastatic Castration-resistant Prostate Cancer | Recruiting | Phase 2 | 2026-10-09 | NCT06401980 | |
| Affera Global Registry | Arrhythmias, Cardiac, Pathologic Processes, Pathological Conditions, Signs and Symptoms, atrial fibrillation, cardiovascular disorder, heart disorder | Active, not recruiting | Not stated | 2026-10-09 | NCT06026345 | |
| Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation. | Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, Lymphatic Abnormalities, Neoplasm, Lymphatic Tissue, Neoplasms by Histologic Type, cystic hygroma, lymphangioma, lymphatic system disorder, neoplasm | Recruiting | Phase 2 / Phase 3 | 2026-10-09 | NCT05948943 | |
| A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes | Nutritional and Metabolic Diseases, autoimmune disease, diabetes mellitus, endocrine system disorder, glucose metabolism disease, immune system disorder, metabolic disease, type 1 diabetes mellitus | Active, not recruiting | Phase 1 / Phase 2 | 2026-10-09 | NCT05791201 | |
| A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus | Skin and Connective Tissue Diseases, autoimmune disease, chronic cutaneous lupus erythematosus, connective tissue disorder, cutaneous lupus erythematosus, discoid lupus erythematosus, immune system disorder, skin disorder, subacute cutaneous lupus erythematosus, systemic lupus erythematosus | Active, not recruiting | Phase 2 / Phase 3 | 2026-10-09 | NCT05531565 | |
| A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, Infant, Newborn, Diseases, cystic fibrosis, hereditary disease, lung disorder, pancreas disorder, respiratory system disorder | Active, not recruiting | Phase 3 | 2026-10-09 | NCT05444257 | |
| Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, Infant, Newborn, Diseases, cystic fibrosis, hereditary disease, lung disorder, pancreas disorder, respiratory system disorder | Active, not recruiting | Phase 3 | 2026-10-09 | NCT05331183 | |
| A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOGAD) | autoimmune disease, autoimmune disorder of the nervous system, immune system disorder, myelin oligodendrocyte glycoprotein antibody-associated disease | Active, not recruiting | Phase 3 | 2026-10-09 | NCT05063162 | |
| Patient Retrospective Outcomes (PRO) | Chronic Pain, Neurologic Manifestations, Pain, Pathological Conditions, Signs and Symptoms, Signs and Symptoms | Recruiting | Not stated | 2026-10-09 | NCT01550575 | |
| A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002) | Advanced Solid Tumors; Malignant Neoplam | Not yet recruiting | Phase 2 | 2026-10-08 | NCT07793942 | |
| The Effect of Olive Leaf Extract Supplementation on Training-induced Skeletal Muscle Functional and Molecular Adaptations in Healthy Volunteers | Exercise Training; Healthy Adult Participants; Neuromuscular Adaptations; Nutritional Intervention | Recruiting | Not applicable | 2026-10-08 | NCT07729072 | |
| A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, blood coagulation disease, blood platelet disease, bone marrow disorder, essential thrombocythemia, hematologic disorder, hemorrhagic disease, thrombocytosis disease | Recruiting | Phase 3 | 2026-10-08 | NCT07623200 | |
| Establishing a Reference Framework for Outcomes After Machine-Preserved Liver Transplantation in Europe | Digestive System Diseases, Fibrosis, Hepatic Insufficiency, Pathologic Processes, Pathological Conditions, Signs and Symptoms, acute liver failure, chronic liver failure, cirrhosis of liver, liver disorder, liver failure | Recruiting | Not stated | 2026-10-08 | NCT07585890 | |
| A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm | Recruiting | Phase 3 | 2026-10-08 | NCT07522073 | |
| Stratification and Treatment in Early Psychosis Study - PROMOTE | Psychotic Disorders, Schizophrenia Spectrum and Other Psychotic Disorders, psychiatric disorder | Not yet recruiting | Phase 3 | 2026-10-08 | NCT07434973 |